The opioidergic-alcohol link: Implications for treatment

CNS Drugs

Volumn 19, Issue 8, 2005, Pages 693-707

  Modesto Lowe, Vania ^a,b   Fritz, Eleanor M ^b  

^a Young Adult Services   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; BETA ENDORPHIN; BETA FUNALTREXAMINE; MORPHINE; NALMEFENE; NALOXONE; NALTREXOL; NALTREXONE; NALTREXONE DERIVATIVE; ONDANSETRON; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR; ALCOHOL; CENTRAL DEPRESSANT AGENT; ENDORPHIN; NARCOTIC ANTAGONIST;

ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; BRAIN REGION; CLINICAL TRIAL; DRINKING BEHAVIOR; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; META ANALYSIS; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALCOHOLISM; ANIMALS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; ENDORPHINS; ETHANOL; HUMANS; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID;

EID: 24144484888     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200519080-00005     Document Type: Review

References (128)

1. Volpicelli JR. Alcohol abuse and alcoholism: an overview. J Clin Psychiatry 2001; 62 Suppl. 20: 4-10
2. O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992; 49: 881-7
3. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876-80
4. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000; 35 (6): 587-93
5. Volpicelli J, Rhines KC, Rhines, et al. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997; 54: 737-42
6. Oncken C, Van Kirk J, Kranzler HR. Adverse effects of oral naltrexone: analyses of data from two clinical trials. Psychopharmacology 2001; 154 (4): 397-402
7. Davis VE, Walsh MJ. Alcohol, amines and alkaloids: a possible biochemical basis for alcohol addiction. Science 1970; 167: 1005-7
8. Cohen G, Collins M. Alkaloids from catecholamines in adrenal tissue: possible role in alcoholism. Science 1970; 167: 1749-51
9. Myers RD. Isoquinolines, beta-carbolines and alcohol drinking: involvement of opioid and dopaminergic mechanisms. Experientia 1989; 45: 436-42
10. Swift RM. Effect of naltrexone on human alcohol consumption. J Clin Psychiatry 1995; 56 Suppl. 7: 24-9
11. Gianoulakis C. Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Alcohol Alcohol 1996; 31 Suppl. 1: 33-42
12. Reisine T, Bell GI. Molecular biology of opioid receptors. Trends Neurol Sci 1993; 16: 506-10
13. Terenius L. Alcohol addition (alcoholism) and the opioid system. Alcohol 1996; 13 (1): 31-4
14. Mucha RF, Herz A. Motivational properties of kappa and mu opioid receptor agonists studies with place and taste preference conditioning. Psychopharmacology 1985; 86: 274-80
15. Di Chiara G, Acquas E, Tanda G. Ethanol as a neurochemical surrogate of conventional reinforcers: the dopamine-opioid link. Alcohol 1996; 13 (1): 13-7
16. Koob GF, Roberts AJ, Kieffer BL, et al. Animal models of motivation for drinking in rodents with a focus on opioid receptor neuropharmacology. Recent Dev Alcohol 2003; 16: 263-81
17. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl) 1997; 129 (2): 99-111
18. Gessa GL, Montoni F, Collo M, et al. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res 1985; 348: 201-3
19. Brodie MS, Pesold C, Appel SB. Ethanol directly excites dopaminergic ventral tegmental reward neurons. Alcohol Clin Exp Res 1999; 23: 1848-52
20. Wozniak KM, Pert A, Mele A, et al. Focal application of alcohols elevates extracellular dopamine in rat brain: a microdialysis study. Brain Res 1991; 540: 31-40
21. Yoshimoto K, McBride WJ, Lumeng L, et al. Alcohol stimulates the release of dopamine and serotonin in the nucleus accumbens. Alcohol 1991; 9: 17-22
22. Hyytia P. Involvement of mu-opioid receptors in alcohol drinking by alcohol-preferring AA rats. Pharmacol Biochem Behav 1993; 45 (3): 697-701
23. Honkanen A, Vilamo L, Wegelius K, et al. Alcohol drinking is reduced by a mu 1- but not by a delta-opioid receptor antagonist in alcohol-preferring rats. Eur J Pharmacol 1996; 304 (1-3): 7-13
24. Stromberg MF, Volpicelli JR, O'Brien CP. Effects of naltrexone administered repeatedly across 30 or 60 days on ethanol consumption using a limited access procedure in the rat. Alcohol Clin Exp Res 1998; 22 (9): 2186-91
25. Kim SG, Stromberg MF, Kim MJ, et al. The effect of antagonists selective for mu- and delta-opioid receptor subtypes on alcohol consumption in C57BL/6 mice. Alcohol 2000; 22 (2): 85-90
26. Ciccocioppo R, Martin-Fardon R, Weiss F. Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats. Neuropsychopharmacology 2002; 27 (3): 391-9
27. June HL, McCane SR, Zink RW. The delta 2-opioid receptor antagonist naltriben reduces motivated responding for ethanol. Psychopharmacology (Berl) 1999; 147 (1): 81-9
28. Roberts AJ, McDonald JS, Heyser CJ, et al. mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther 2000; 293 (3): 1002-8
29. Roberts AJ, Gold LH, Polis I, et al. Increased ethanol self-administration in delta-opioid receptor knockout mice. Alcohol Clin Exp Res 2001; 25 (9): 1249-56
30. Spanagel R, Herz A, Shippenberg TS. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem 1990; 55: 1734-40
31. Gianoulakis C, Hutchison WD, Kalant H. Effects of ethanol treatment and withdrawal on biosynthesis and processing proopiomelanocortin by the rat neurointermediate lobe. Endocrinology 1988; 122 (3): 817-25
32. Gianoulakis C. Characterization of the effects of acute ethanol administration on the release of beta-endorphin peptides by the rat hypothalamus. Eur J Pharmacol 1990; 180 (1): 21-9
33. de Waele JP, Gianoulakis C. Effects of single and repeated exposures to ethanol on hypothalamic beta-endorphin and CRH release by the C57BL/6 and DBA/2 strains of mice. Neuroendocrinology 1993; 57 (4): 700-9
34. de Waele JP, Papachristou DN, Gianoulakis C. The alcohol-preferring C57BL/6 mice present an enhanced sensitivity of the hypothalamic beta-endorphin system to ethanol than the alcohol-avoiding DBA/2 mice. J Pharmacol Exp Ther 1992; 261 (2): 788-94
35. Rasmussen DD, Bryant CA, Boldt BM, et al. Acute alcohol effects on opiomelanocortinergic regulation. Alcohol Clin Exp Res 1998; 22 (4): 789-801
36. Gianoulakis C, Barcomb A. Effect of acute ethanol in vivo and in vitro on the beta-endorphin system in the rat. Life Sci 1987; 40 (1): 19-28
37. Thiagarajan AB, Mefford IN, Eskay RL. Single-dose ethanol administration activates the hypothalamic-pituitary-adrenal axis: exploration of the mechanism of action. Neuroendocrinology 1989; 50 (4): 427-32
38. de Waele JP, Kiianmaa K, Gianoulakis C. Spontaneous and ethanol stimulated in vitro release of β-endorphin by the hypothalamus of AA and ANA rats. Alcohol Clin Exp Res 1994; 18: 1468-73
39. Gianoulakis C, Hutchison WD, Kalant H. Effects of ethanol treatment and withdrawal on biosynthesis and processing of proopiomelanocortin by the rat neurointermediate lobe. Endocrinology 1988; 122 (3): 817-25
40. Seizinger BR, Bovermann K, Hollt V, et al. Enhanced activity of the beta-endorphinergic system in the anterior and neurointermediate lobe of the rat pituitary after chronic treatment with ethanol liquid diet. J Pharmacol Exp Ther 1984; 230 (2): 455-61
41. Dave JR, Eiden LE, Karanian JW, et al. Ethanol exposure decreases pituitary corticotropin-releasing factor binding, adenylate cyclase activity, proopiomelanocortin biosynthesis, and plasma beta-endorphin levels in the rat. Endocrinology 1986; 118 (1): 280-6
42. Seizinger BR, Bovermann K, Maysinger D, et al. Differential effects of acute and chronic ethanol treatment on particular opioid peptide systems in discrete regions of rat brain and pituitary. Pharmacol Biochem Behav 1983; 18 Suppl. 1: 361-9
43. Schulz R, Wuster M, Duka T, et al. Acute and chronic ethanol treatment changes endorphin levels in brain and pituitary. Psychopharmacology (Berl) 1980; 68 (3): 221-7
44. Adams ML, Cicero TJ. Effects of alcohol on beta-endorphin and reproductive hormones in the male rat. Alcohol Clin Exp Res 1991; 15 (4): 685-92
45. Angelogianni P, Gianoulakis C. Chronic ethanol increased proopiomelanocortin gene expression in the rat hypothalamus. Neuroendocrinology 1993; 57 (1): 106-14
46. Scanlon MN, Lazar-Wesley E, Grant KA, et al. Propiomelanocortin messenger RNA is decreased in the mediobasal hypothalamus of rats made dependent on ethanol. Alcohol Clin Exp Res 1992; 16: 1147-51
47. Marinelli PW, Kiianmaa K, Gianoulakis C. Opioid propeptide mRNA content and receptor density in the brains of AA and ANA rats. Life Sci 2000; 66 (20): 1915-27
48. de Waele JP, Gianoulakis C. Enhanced activity of the brain beta-endorphin system by free-choice ethanol drinking in C57BL/6 but not DBA/2 mice. Eur J Pharmacol 1994; 258 (1-2): 119-29
49. Gianoulakis C, de Waele JP, Kiianmaa K. Differences in the brain and pituitary beta-endorphin system between the alcohol-preferring AA and alcohol-avoiding ANA rats. Alcohol Clin Exp Res 1992; 16 (3): 453-9
50. Jamensky NT, Gianoulakis C. Content of dynorphins and kappa-opioid receptors in distinct brain regions of C57BL/6 and DBA/2 mice. Alcohol Clin Exp Res 1997; 21 (8): 1455-64
51. Froehlich JC. Genetic factors in alcohol self-administration. J Clin Psychiatry 1995; 56 Suppl. 7: 15-23
52. Blum K, Briggs AH. Opioid peptides and genotypic responses to ethanol. Biog Amines 1988; 5: 527-33
53. Li X-W, Li T-K, Froelich JC. Enhanced sensitivity of the nucleus accumbens proenkephalin system to alcohol in rats selectively bred for alcohol preference. Brain Res 1998; 794: 35-47
54. Nylander I, Hyytia P, Forsander O, et al. Differences between alcohol-preferring (AA) and alcohol-avoiding (ANA) rats in the prodynorphine and proenkephalin systems. Alcohol Clin Exp Res 1994; 18 (5): 1272-9
55. Ng GYK, O'Dowd BE, George SR. Genotypic differences in mesolimbic enkephalin gene expression in DBA/2J and C57BL/6J inbred mice. Eur J Pharmacol 1996; 311: 45-52
56. Jamensky NT, Gianoulakis C. Content of dynorphins and kappa-opioid receptors in distinct brain regions of C57BL/6 and DBA/2 mice. Alcohol Clin Exp Res 1997; 21 (8): 1455-64
57. de Waele JP, Kiianmaa K, Gianoulakis C. Distribution of the mu and delta opioid binding sites in the brain of the alcohol-preferring AA and alcohol-avoiding ANA lines of rats. J Pharmacol Exp Ther 1995; 275 (1): 518-27
58. Learn JE, Chernet E, McBride WJ, et al. Quantitaive autoradiography of mu-opioid receptors in the CNS of high-alcohol-dromlomg (HAD) and low-alcohol-drinking (LAD) rats. Alcohol Clin Exp Res 2001; 25 (4): 524-30
59. de Waele JP, Gianoulakis C. Characterization of the mu and delta opioid receptors in the brain of the C57BL/6 and DBA/2 mice, selected for their differences in voluntary ethanol consumption. Alcohol Clin Exp Res 1997; 21 (4): 754-62
60. Fadda P, Tronci S, Colombo G, et al. Differences in the opioid system in selected brain regions of alcohol-preferring and alcohol-nonpreferring rats. Alcohol Clin Exp Res 1999; 23 (8): 1296-305
61. Soini SL, Ovaska T, Honkanen A, et al. Brain opioid receptor binding of [3H] CTOP and [3H] naltrindole in alcohol-preferring AA and alcohol-avoiding ANA rats. Alcohol 1998; 15 (3): 227-32
62. Soini SL, Honkanen A, Hyytia P, et al. Ethylketocyclazocine binding to brain opioid receptor subtypes in alcohol-preferring AA and alcohol-avoiding ANA rats. Alcohol 1999; 18 (1): 27-34
63. Soini SL, Hyytia P, Korpi ER. Brain regional mu-opioid receptor function in rat lines selected for differences in alcohol preference. Eur J Pharmacol 2002; 448 (2-3): 157-63
64. Gianoulakis C, Beliveau D, Angelogianni P, et al. Different pituitary beta-endorphin and adrenal cortisol response to ethanol in individuals with high and low risk for future development of alcoholism. Life Sci 1989; 45 (12): 1097-109
65. Froehlich JC, Zink RW, Li TK, et al. Analysis of heritability of hormonal responses to alcohol in twins: beta-endorphin as a potential biomarker of genetic risk for alcoholism. Alcohol Clin Exp Res 2000; 24 (3): 265-77
66. Sinclair JD. Morphine suppresses alcohol drinking regardless of prior alcohol access duration. Pharmacol Biochem Behav 1974; 2: 409-12
67. Ho AKS, Chen RCA, Morrison JM. Interactions of narcotics, narcotic antagonists, and ethanol during acute, chronic, and withdrawal states. Ann N Y Acad Sci 1976; 281: 297-310
68. Ross D, Hartmann RJ, Geller I. Ethanol preference in the hamster: effects of morphine sulfate and naltrexone, a long-acting morphine antagonist. Proc West Pharmacol Soc 1976; 19: 326-30
69. Reid LD, Hunter GA. Morphine and naloxone modulate intake of ethanol. Alcohol 1984; 1: 33-7
70. Beaman CM, Hunter GA, Dunn LL, et al. Opioids, benzodiazepines and intake of ethanol. Alcohol 1984; 1 (1): 39-42
71. Hubbell CL, Czirr SA, Hunter GA, et al. Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations. Alcohol 1986; 3: 39-54
72. Hubbell CL, Czirr SA, Reid LD. Persistence and specificity of small doses of morphine on intake of alcoholic beverages. Alcohol 1987; 4 (3): 149-56
73. Reid LD, Czirr SA, Bensinger CC, et al. Morphine and diprenorphine together potentiate intake of alcoholic beverages. Alcohol 1987; 4: 161-8
74. Hubbell CL, Abelson ML, Burkhardt CA, et al. Constant infusions of morphine and intakes of sweetened ethanol solution among rats. Alcohol 1988; 5: 409-15
75. Reid LD, Delconte JD, Nichols ML, et al. Tests of opioid deficiency hypotheses of alcoholism. Alcohol 1991; 8: 247-57
76. Wild KD, Reid LD. Modulation of ethanol-intake by morphine: evidence for a central site of action. Life Sci 1990; 47 (14): 49-54
77. Reid LD. Endogenous opioids and alcohol dependence: opioid alkaloids and the propensity to drink alcoholic beverages. Alcohol 1996; 13: 5-11
78. Volpicelli JR, Ulm RR, Hopson J. Alcohol drinking in rats during and following morphine injections. Alcohol 1991; 8: 289-92
79. Anglin MD, Almog IJ, Fisher DG, et al. Alcohol use by heroin addicts: evidence for an inverse relationship: a study of methadone maintenance and drug-free treatment samples. Am J Drug Alcohol Abuse 1989; 15 (2): 191-207
80. Hser YI, Anglin MD, Powers K. Longitudinal patterns of alcohol use by narcotics addicts. Recent Dev Alcohol 1990; 8: 145-71
81. Almog YJ, Anglin MD, Fisher DG. Alcohol and heroin use patterns of narcotics addicts: gender and ethnic differences. Am J Drug Alcohol Abuse 1993; 19 (2): 219-38
82. Stromberg MF, Rukstalis MR, Mackler SA, et al. A comparison of the effects of 6-beta naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited-access procedure in rats. Pharmacol Biochem Behav 2002; 72 (1-2): 483-90
83. Cramer CM, Gardell LR, Boedeker KL, et al. Isradipine combined with naltrexone persistently reduces the reward-relevant effects of cocaine and alcohol. Pharmacol Biochem Behav 1998; 60 (2): 345-56
84. Stromberg MF, Mackler SA, Volpicelli JR, et al. Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption. Alcohol 2001; 23 (2): 109-16
85. Stromberg MF, Sengpiel T, Mackler SA, et al. Effect of naltrexone on oral consumption of concurrently available ethanol and cocaine in the rat. Alcohol 2002; 28 (3): 169-79
86. Bienkowski P, Kostowski W, Koros E. Ethanol-reinforced behaviour in the fat: effects of naltrexone. Eur J Pharmacol 1999; 374 (3): 321-7
87. Swift RM, Whelihan W, Kuznetsov O, et al. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 1994; 151 (10): 1463-7
88. Volpicelli JR, Watson NT, King AC, et al. Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry 1995; 152 (4): 613-5
89. Middaugh LD, Kelley BM, Cuison Jr ER, et al. Naltrexone effects on ethanol reward and discrimination in C57BL/6 mice. Alcohol Clin Exp Res 1999; 23 (3): 456-64
90. McCaul ME, Wand GS, Eissenberg T, et al. Naltrexone alters subjective and psychomotor responses to alcohol heavy drinking subjects. Neuropsychopharmacology 2000; 22: 480-92
91. O'Malley SS, Krishnan-Aarin S, Farren C, et al. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl) 2002; 160 (1): 19-29
92. Coonfield DL, Hill KG, Kaczmarek HJ, et al. Low doses of naltrexone reduce palatability and consumption of ethanol in outbred rats. Alcohol 2002; 26 (1): 43-7
93. Ross D, Hartmann RJ, Geller I. Ethanol preference in the hamster: effects of morphine sulfate and naltrexone, a long-acting morphine antagonist. Proc West Pharmacol Soc 1976; 19: 326-30
94. Nation JR, Horger BA, Pugh CK, et al. The effects of naltrexone on cadmium-induced increased in oral ethanol self-administration. Alcohol 1990; 7: 17-20
95. Berman RF, Lee JA, Olson KL, et al. Effects of naloxone on ethanol dependence in rats. Drug Alcohol Depend 1984; 13: 245-54
96. Holter SM, Spanagel R. Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats. Psychopharmacology (Berl) 1999; 145 (4): 360-9
97. Cowen MS, Rezvani AH, Jarrott B, et al. Ethanol consumption by Fawn-Hooded rats following abstinence: effect of naltrexone and changes in mu-opioid receptor density. Alcohol Clin Exp Res 1999; 23 (6): 1008-14
98. Phillips TJ, Wenger CD, Dorow JD. Naltrexone effects on ethanol drinking acquisition and on established ethanol consumption in C57BL/6J mice. Alcohol Clin Exp Res 1997; 21 (4): 691-702
99. Middaugh LD, Bandy AL. Naltrexone effects on ethanol con-sumption and response to ethanol conditioned cues in C57BL/6 mice. Psychopharmacology (Berl) 2000; 151 (4): 321-7
100. Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nelmefene HCl for alcohol dependence. Alcohol Clin Exp Res 1994; 18: 1162-7
101. Mason BJ, Salvato FR, Williams LD, et al. A double-blind, placebo-controlled study of nalmefene for alcohol dependence. Arch Gen Psychiatry 1999; 56 (8): 719-24
102. Anton RF, Moak DH, Waid LR. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999; 156 (11): 1758-64
103. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs nefazodone for treatment of alcohol dependence placebo-controlled trial. Neuropsychopharmacology 2000; 22 (5): 493-503
104. Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001; 25 (11): 1634-47
105. Heinala P, Alhol H, Kiianmaa K, et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 2001; 21 (3): 287-92
106. Krystal JH, Cramer JA, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345: 1734-9
107. Monterosso JR, Flannery BA, Pettinati HM, et al. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 2001; 10 (3): 258-68
108. Morris PL, Hopwood M, Whelan G, et al. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 2001; 96 (11): 1565-73
109. Latt NC, Jurd S, Houseman J, et al. Naltrexone in alcohol dependence: a randomized controlled trial of effectiveness in a standard clinical setting. Med J Aust 2002; 176 (11): 530-4
110. Gastpar M, Bonnet U, Boning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psycopharmacol 2002; 22 (6): 592-8
111. Balldin J, Berglund M, Borg S, et al. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 2003; 23 (7): 1142-9
112. Kiefer F, Jaun H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60 (1): 92-9
113. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25 (9): 1335-41
114. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol 2001; 36 (6): 544-52
115. Pettinati HM, Volpicelli JR, Pierce Jr JD, et al. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 2000; 19 (1): 71-83
116. Jaffe AJ, Rounsaville B, Chang G, et al. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 1996; 64 (5): 1044-53
117. Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcoholism Clin Exp Res 1998; 22 (5): 1074-9
118. Modesto-Lowe V. Naltrexone depot. IDrugs 2002; 5 (8): 835-8.
119. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial [published erratum appears in JAMA 2005 Apr 27; 293 (16): 1978 and JAMA 2005 Jun 15; 293 (23): 2864. JAMA 2005 Apr 27; 293 (13): 1617-25
120. Kranzler H, Liou S, Loewy J, et al. Effect of long-acting injectable naltrexone on quality of life [abstract]. American Psychiatric Association Annual Meeting 2005 May 21-26; Atlanta (GA)
121. O'Malley SS. Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. Alcohol Alcohol 1996; Suppl. 1: 77-81
122. Holter SM, Spanagel R. Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats. Psychopharmacology (Berl) 1999; 145 (4): 360-9
123. Kranzler HR, Armeli S, Tennen H, et al. Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol 2003; 23 (3): 294-304
124. Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res 2000; 24: 737-42
125. De Witte P, Littleton J, Parot P, et al. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 2005; 19 (6): 517-37
126. Johnson BA. Role of the seroteoergic system in the neurobiology of alcoholism: implications for treatment. CNS Drugs 2004; 18 (15): 1105-18
127. Michel ME, Bolger G, Weissman BA. Binding of a new opiate antagonist, nalmefene, to rat brain membrains. Methods Find Exp Clin Pharmacol 1985; 7: 175-7
128. The COMBINE Study Research Group. Testing combined pharmacotherapies and behavioural interventions for alcohol dependence: a pilot feasibility study. Alcohol Clin Exp Res 2003; 27 (7): 1123-31